VLP Therapeutics, Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 3 name spellings.
0
Ending by 2030
Feb 2033
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Feb 20, 2027The maintenance fee for Virus like particle comprising modified envelope protein E3 (US 10,385,101) comes due Feb 20, 2027. Unpaid by Aug 20, 2027, it lapses early.
- 1 fee due May 5, 2027The maintenance fee for Virus like particle comprising PD-1 antigen or PD-1 ligand antigen (US 10,464,986) comes due May 5, 2027. Unpaid by Nov 5, 2027, it lapses early.
- 1 fee due Aug 2, 2027The maintenance fee for Virus like particle composition (US 9,249,191) comes due Aug 2, 2027. Unpaid by Feb 2, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 20, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,249,191 | Virus like particle composition In force · From the USPTO record | In force | From the USPTO record | |
| US 11,345,726 | Chikungunya virus (CHIKV) or Venezuelan equine encephalitis virus (VEEV) virus-like particles comprising heterologous antigens inserted into the envelope protein In force · From the USPTO record | In force | From the USPTO record | |
| US 9,512,190 | Malaria vaccine In force · From the USPTO record | In force | From the USPTO record | |
| US 10,464,986 | Virus like particle comprising PD-1 antigen or PD-1 ligand antigen In force · From the USPTO record | In force | From the USPTO record | |
| US 9,969,986 | Virus like particle comprising modified envelope protein E3 In force · From the USPTO record | In force | From the USPTO record | |
| US 10,385,101 | Virus like particle comprising modified envelope protein E3 In force · From the USPTO record | In force | From the USPTO record | |
| US 10,098,943 | Flavivirus virus like particle In force · From the USPTO record | In force | From the USPTO record | |
| US 10,166,281 | Method and composition for modulating immune response In force · From the USPTO record | In force | From the USPTO record | |
| US 12,227,770 | Alphavirus Replicon Particle In force · High confidence | In force | High confidence | |
| US 12,742,182 | Cytokine Immunotherapy In force · High confidence | In force | High confidence |
Also on record, not counted in the 13: 1 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 pending · 1 abandoned · 4 no status recorded